MBLI QuickSwitch™ kit technology aims to replicate the immune response by mimicking peptide exchange on an MHC molecule.
Rapid and Reliable Custom Tetramer Generation for T-Cell Staining
Streamline the detection of CD4 T cells with QuickSwitch™ Class II Quant Tetramer Kits
Use QuickSwitch™ Class II Quant Tetramer to investigate peptide-MHC binding affinities & conclude with your specialised CD4+ T cell detection reagent!
2023 Advancements in Research with QuickSwitch™ Custom Tetramer Kits
Here are the highlights of some of the influential publications that have utilised MBLI QuickSwitch™ Tetramer Kits in 2023.
The invaluable role of QuickSwitch™ kits in validating predicted results
Wang, Wenfeng, et al 2023, selected the top 15 top peptides for self-antigen for their study. By using the QuickSwitch™ kit, they successfully switched 6 peptides to the tetramer complex with an efficiency of over 75%.
Validation of Neoantigen In Silico Prediction using QuickSwitch™ Kits
Research findings indicate that neoantigens have the potential to activate tumour-specific T-cell-mediated anti-tumour immune responses.
Human MHC Class II QuickSwitch™ Platform is used to Identify SARS-CoV-2 Virus Derived Peptides
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research) MBL International described how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether that
How to Identify SARS-CoV-2 Virus Derived Peptides
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research), MBL International describes how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether
Find Human MHC Class I Dominant Peptides
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research) MBL International described how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether
Comparing Theoretical Peptide-MHC Binding Affinity to Real Values produced by the QuickSwitch™ Platform
In a previous blog post (How to screen SARS-CoV-2 peptides to facilitate T cell research) MBL International described how the immune system samples all of the pathogenic proteins by looking at the small fragments of each protein and determining whether
How to screen SARS-CoV-2 peptides to facilitate T cell research
Whenever our immune system is faced with a challenge, be it a multicellular parasite, a bacteria, a virus, or even cancer, this threat is detected and sampled primarily by the protein sequence of the pathogen in question. Other aspects of